Health Economics›Acute myeloid leukemia›Upfront induction therapy standard and older "fit" patients

Upfront induction therapy standard and older "fit" patients

Acute myeloid leukemia · 17 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
7+3d and GO Variant #01	—	R 134 712	7d	—	—	—	—	1
DA 3+10, GO Variant #01	—	R 51 644	10d	—	—	—	—	1
DAC Variant #01	—	R 45 913	7d	—	24.0 mo	—	—	1
FLAG-Ida Variant #01	—	R 35 219	28d	—	~5.4 mo	—	—	3
7+3i and Sorafenib Variant #01	—	R 26 368	7d	—	—	—	—	—
ADE (high-dose Ara-C) Variant #01	—	R 24 287	6d	—	—	—	—	1
AIE Variant #01	—	R 19 409	7d	—	—	—	—	—
MEC Variant #01	—	R 19 351	28d	—	10.0 mo	—	—	1
ICL Variant #01 Partial	—	R 19 001	7d	—	—	—	—	1
CIA Variant #01 Partial	—	R 17 528	5d	—	—	—	—	—
7+3i Variant #01	—	R 17 152	7d	—	12.9 mo	—	—	2
7+3m Variant #01	—	R 13 063	7d	—	~6.7 mo	—	—	1
DA 3+10 Variant #01	—	R 12 698	10d	—	—	—	—	2
ADE (standard-dose Ara-C) Variant #07	—	R 11 856	10d	—	—	—	—	1
7+3d and Glasdegib Variant #01 Partial	—	R 11 746	28d	—	—	—	—	—
7+3d Variant #01	—	R 6 129	—	—	15.1 mo	—	—	11
HAA Variant #01 Partial	—	R 513	7d	—	—	—	—	—

17 of 17 regimens shown